Published in Cancer Weekly, February 10th, 2004
"Adaphostin (NSC 680410), an analog of the tyrphostin AG957, was previously shown to induce Bcr/abl downregulation followed by loss of clonogenic survival in chronic myelogenous leukemia (CML) cell lines and clinical samples," investigators in the United States report.
"Adaphostin demonstrated selectivity for CML myeloid progenitors in vitro and remained active in K562 cells selected for imatinib mesylate resistance. In the present study, the mechanism of action of adaphostin was investigated in greater detail in vitro," wrote J. Chandra and colleagues,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.